A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive breast cancer.
Epistemonikos ID: ef2ea3592017b259cc997882ee3826d2b83cab13
First added on: May 11, 2024